
Logomix Logomix Biotechnologies is a US/Japan company transforming iPSC engineering through Geno-Writing™, our proprietary genome platform. It enables rapid, precise, allele-specific, and megabase-scale modifications—purpose-built for ex vivo development of next-generation cell therapies. As a first application of this platform, we are focusing on the development of hypoimmune iPSC lines through our advanced HLA locus engineering and combinatorial transgene screening, while minimizing impact on differentiation potential. We are also developing genomic modification strategies leveraging Geno-Writing™ to enhance lineage fidelity post-transplantation, addressing key barriers to safety and efficacy in cell therapy. In our Type 1 Diabetes program, Geno-Writing™ has yielded iPSC-derived beta cells with improved insulin secretion and reduced off-target differentiation. We are continuing to engineer these cells further to better meet the functional demands of clinical applications. Technology Developer

Logomix

Logomix Biotechnologies is a US/Japan company transforming iPSC engineering through Geno-Writing™, our proprietary genome platform. It enables rapid, precise, allele-specific, and megabase-scale modifications—purpose-built for ex vivo development of next-generation cell therapies. As a first application of this platform, we are focusing on the development of hypoimmune iPSC lines through our advanced HLA locus engineering and combinatorial transgene screening, while minimizing impact on differentiation potential. We are also developing genomic modification strategies leveraging Geno-Writing™ to enhance lineage fidelity post-transplantation, addressing key barriers to safety and efficacy in cell therapy. In our Type 1 Diabetes program, Geno-Writing™ has yielded iPSC-derived beta cells with improved insulin secretion and reduced off-target differentiation. We are continuing to engineer these cells further to better meet the functional demands of clinical applications.

Technology Developer